Medical Xpress

Squid studies suggest new route to therapy for ALS, targeting synaptic dysfunction

"One summer, I chatted with Rodolfo Linas at the MBL, who has been doing synaptic recordings in the squid for many decades," Song says. "I helped his lab with some electron microscopy on the squid ...
The Victoria Advocate

Spinogenix Announces FDA-Authorized Expanded Access Program for SPG302, the First Synaptic Regenerative Therapy to Treat ALS

LOS ANGELES, May 5, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients ...
KTLA

Spinogenix's SPG302, the First Synaptic Regenerative Therapy to Treat ALS, Granted Orphan Drug Designation by the European Medicines Agency

LOS ANGELES, June 3, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients ...
Seeking Alpha

Spinogenix Announces Full Enrollment in its Phase 2 Trial Evaluating SPG302 as a First-in-Class Synaptic Regenerative Therapy for Alzheimer's Disease

FDA Clears IND in Alzheimer's Disease, Enabling Future Expansion to U.S. LOS ANGELES, June 24, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering ...
Science Daily

Squid studies suggest new route to therapy for ALS, targeting synaptic dysfunction

"Squid studies suggest new route to therapy for ALS, targeting synaptic dysfunction." ScienceDaily. www.sciencedaily.com / releases / 2020 / 06 / 200601134547.htm (accessed February 7, 2026).
EurekAlert!

Squid studies suggest new route to therapy for ALS, targeting synaptic dysfunction

WOODS HOLE, Mass. -- Amyotrophic lateral sclerosis (ALS) is one of the most devastating adult-onset neurodegenerative diseases. Patients, including the late actor/playwright Sam Shepard, become ...